Pfizer Inc. (NYSE:PFE) insider Mikael Dolsten sold 69,699 shares of the business’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $36.59, for a total transaction of $2,550,286.41. Following the completion of the sale, the insider now directly owns 120,784 shares of the company’s stock, valued at $4,419,486.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Mikael Dolsten also recently made the following trade(s):
- On Friday, March 2nd, Mikael Dolsten sold 13,986 shares of Pfizer stock. The stock was sold at an average price of $35.85, for a total transaction of $501,398.10.
Pfizer stock opened at $36.27 on Thursday. The company has a market cap of $216,267.59, a price-to-earnings ratio of 10.33, a P/E/G ratio of 2.05 and a beta of 0.91. Pfizer Inc. has a one year low of $31.67 and a one year high of $39.43. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35.
Pfizer declared that its board has approved a stock buyback plan on Monday, December 18th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board of directors believes its shares are undervalued.
A number of large investors have recently added to or reduced their stakes in PFE. Mckinley Capital Management LLC Delaware acquired a new position in shares of Pfizer in the 2nd quarter valued at $103,000. Earnest Partners LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $105,000. First Dallas Securities Inc. acquired a new position in shares of Pfizer in the 4th quarter valued at $118,000. Woodard & Co. Asset Management Group Inc. ADV acquired a new position in shares of Pfizer in the 4th quarter valued at $118,000. Finally, Herndon Capital Management LLC bought a new stake in shares of Pfizer in the 2nd quarter worth about $120,000. Hedge funds and other institutional investors own 71.16% of the company’s stock.
Several analysts have commented on the stock. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, January 30th. SunTrust Banks reissued a “hold” rating and issued a $40.00 target price (up from $33.00) on shares of Pfizer in a research report on Monday, January 29th. Morgan Stanley boosted their price objective on shares of Pfizer from $41.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. UBS set a $42.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Finally, Societe Generale set a $40.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $39.40.
TRADEMARK VIOLATION WARNING: “Mikael Dolsten Sells 69,699 Shares of Pfizer Inc. (PFE) Stock” was originally posted by BBNS and is owned by of BBNS. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://baseballnewssource.com/2018/03/22/mikael-dolsten-sells-69699-shares-of-pfizer-inc-pfe-stock/2035344.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.